BACKGROUND: Stereotactic lesion in the Forel's field H (campotomy) was proposed in 1963 to treat Parkinson disease (PD) symptoms. Despite its rationale, very few data on this approach have emerged. Additionally, no study has assessed its effects on nonmotor symptoms, neuropsychological functions and quality of life. OBJECTIVE: To provide a prospective 2-yr assessment of motor, nonmotor, neuropsychological and quality of life variables after unilateral campotomy. METHODS: Twelve PD patients were prospectively evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS), the Dyskinesia Rating Scale and the Parkinson's disease quality of life questionnaire (PDQ39) before campotomy, and after 6 and 24 mo. Nonmotor, neuropsychiatric, neuropsychological and quality of life variables were assessed. The impact of PD on global health was also rated. RESULTS: A significant reduction in contralateral rest tremor (65.7%, P < .001), rigidity (87.8%, P < .001), bradykinesia (68%, P < .001) and axial symptoms (24.2%, P < .05) in offmedication condition led to a 43.9% reduction in UPSDRS III scores 2 yr after campotomy (P < .001). Gait improved by 31.9% (P < .05) and walking time to cover 7 m was reduced by 43.2% (P < .05). Pain decreased by 33.4% (P < .01), while neuropsychiatric and neuropsychological functions did not change. Quality of life improved by 37.8% (P < .05), in line with a 46.7% reduction of disease impact on global health (P < .001). CONCLUSION: A significant 2-yr improvement of motor symptoms, gait performance and pain was obtained after unilateral campotomy without significant changes to cognition. Quality of life markedly improved in parallel with a significant reduction of PD burden on global health. F ibers connecting basal ganglia structures to the cerebral cortex, thalamus and cerebellum have been very early targeted by different neurosurgical approaches to control Parkinson disease (PD) symptoms. 1-3 ABBREVIATIONS: AC, anterior commissure; ADL, activities of daily living; DBS, deep brain stimulation; D.im.e, Dorsointermedius externus; FF, Forel's Field H; L.po, Lateropolaris; PC, posterior commissure; PD, Parkinson disease; PPN, pedunculopontine tegmental nucleus; QoL, quality of life; SD, standard deviation; SEM, standard error of the mean; STN, subthalamic nucleus; V.im, Ventrointermedius; V.o.a, Ventro-oralis anterior thalamic nucleus; V.o.p, Ventro-oralis posterior thalamic nucleus; VAS, visual analogue pain intensity scale; UDysRS, Unified Dyskinesia Rating Scale; UPDRS, Unified Parkinson's Disease Rating Scale Supplemental digital content is available for this article at www.neurosurgery-online.com.
In addition, when high-frequency stimulation of the STN was used, the most effective contacts of quadripolar electrodes were located in the rostrodorsal part of the STN, close to the zona incerta and the Forel's Field H (FF). 6 These data emphasize that functional modulation of subthalamic fibers is an important factor to achieve a satisfactory motor improvement in PD, using either lesion or electrical stimulation.
Among the subthalamic fiber tracts, the FF and its vicinity comprise a complex bundle of pallidofugal, cerebellothalamic and pallidomesencephalic axons. [7] [8] [9] Pallidothalamic fibers project predominantly onto Lateropolaris (L.po), Ventro-oralis anterior (V.o.a) and Ventro-oralis posterior (V.o.p) thalamic nuclei, while cerebellar fibers terminate preferentially into the Ventrointermedius (V.im) and Dorsointermedius externus (D.im.e.) thalamic nuclei (Hassler nomenclature). These thalamic nuclei project to motor, premotor and supplementary motor cortical areas. 10, 11 As to the pallidomesencephalic fibers, they project to mesencephalic locomotor area and are likely involved in axial motor functions. 12 Despite these anatomical considerations, only one surgical team has reported results based on the direct approach of the FF in PD patients during the last 5 decades. [13] [14] [15] Using stereotactic lesions centered at the FF (campotomy), significant reductions of tremor, rigidity and bradykinesia were reported. 14 However, no study so far analyzed the possible effects of campotomy on nonmotor symptoms, cognitive functions and quality of life (QoL) in PD patients. In this study, we performed a comprehensive and prospective evaluation of motor and nonmotor variables in 12 PD patients after unilateral campotomy followedup for 2 yr. We hypothesized that reduction in motor symptoms would result in significant improvement in QoL after surgery, while neuropsychological and neuropsychiatric effects would be limited or absent.
METHODS Patients
We enrolled 12 out of 19 right-handed patients with advanced PD in this prospective open-label clinical trial. Data from 7 patients were excluded as they lived far away from our center and were followed-up by local Neurologists. All patients were recruited and operated on at a single hospital from January to July 2014. Clinical and imaging data from each subject was identified by 2 digits to assure confidentiality. Exclusion criteria were major psychiatric illness, PD dementia, previous intracranial surgery, major clinical disorders and poor clinical response to levodopa challenge (motor scores reduction in the Unified Parkinson's Disease Rating Scale -UPDRS III -below 30%). This clinical trial adheres to the Standard Protocol Items: Recommendations for Interventional Trials -2013 (SPIRIT) guidelines and was approved by the institutional review board. All written informed consents were obtained by the first author.
This study is registered in the Brazilian Clinical Trials Registry (http://www.ensaiosclinicos.gov.br/rg/RBR-9rh8vr/5 Register Number: RBR-9rh8vr).
Clinical, Neuropsychological and Neuropsychiatric Assessments
Primary outcomes were motor symptoms and QoL at 6 mo and 2 yr after surgery (means ± SEM). Secondary outcomes were neuropsychological, neuropsychiatric and nonmotor symptoms. Evaluations were performed preoperatively, 6 and 24 mo after surgery using UPDRS and Hoehn and Yahr (H&Y) scales, the CAPSIT-PD recommended by the core assessment program for intracerebral transplantation and the Unified Dyskinesia Rating Scale (UDysRS). We assessed pain intensity through visual analogue pain intensity scale -VAS, the overall nonmotor symptoms (nonmotor symptoms scale), fatigue severity (fatigue severity scale) and sleep quality (SCOPA-sleep). Neuropsychiatric evaluation excluded dementia and other major psychiatric disorders using the Neuropsychiatric Inventory, Scales for Outcomes in PD -Psychiatric Complications (SCOPA-PC) and Beck Depression Inventory. The neuropsychological evaluation comprised tests recommended by the movement disorders society. QoL was estimated through the Brazilian version of PD QoL questionnaire -PDQ-39. 16 The subjective impact of PD on global health was rated preoperatively and at 2 years according to a 5-point Likert scale as follows: 1not at all, 2 -slightly, 3 -moderately, 4 -very, 5 -extremely. All motor scales were performed in off and onmedication conditions, while nonmotor functions were evaluated only in onmedication condition. Adverse events were collected and reported according to the Medical Dictionary for Regulatory Activities, version 17 (MedDRA 17.0 -2014). If no spontaneous complaints have occurred, an active inquiry was performed.
Surgical Procedure
Anatomical targeting was performed by fusing a stereotactic tomography with a nonstereotactic volumetric 1.5T Magnetic Resonance Imaging (MRI). The FF localization was estimated as following: X = 7.5 mm from the lateral border of the third ventricle at the anterior commissure -posterior commissure level (AC-PC); Y = 1 mm posterior to the midcommissural point; Z = 1 mm inferior to the AC-PC level. 17 Microelectrode recordings were performed using a set of 2 or 3 parallel tungsten microelectrodes (microTargeting R electrodes, FHC, Greenville, Massachusetts). Recordings were started at 5 mm above the anatomical target and performed every millimeter until recording spikes from STN neurons. STN cell firings were used as an internal marker, not only to estimate the FF position (anterior, medial and superior to STN) but also to avoid as much as possible STN lesions. Macrostimulation (130 Hz, 100 μs, 1 to 3 V) and neurological assessment began 5 mm above the target and were performed every millimeter on a trajectory lacking STN spikes. Therefore, campotomies were always performed medially to the electrophysiologically defined STN. In the superoinferior axis, the electrodes were placed 1 mm superior to the beginning of STN recordings and contralateral to the worst clinical side. One single radiofrequency lesion was made by means of a 1.1 mm diameter and 5.0 mm length exposed tip electrode. Special attention was drawn to avoid the mammillothalamic tract, which is located slightly medial and anterior to FF. A test at 50 • C during 60 s was followed by a definitive lesion (75 • C, 60 s) over the trajectory yielding the best clinical responses after macrostimulation (Cosman RFG 4 A R , Burlington, Massachusetts).
Postoperative Management
Patients were discharged 3 d after surgery on average. We repeated a nonstereotactic MRI 6 mo after surgery and fused it with the surgical stereotactic tomography to determine the mean volume ± 1 standard deviation (SD) and the corresponding mass center of the lesion.
Statistical Analysis
Data were expressed as means and standard errors of the mean (SEM), except for the anatomical characteristics of the lesions (means and Standard Deviation -SD). They were tested for normality using D'Agostino & Pearson test. One-way repeated-measures Analyses of Variance (ANOVA) were applied on normal distributed variables, while the Friedman test was applied on skewed distributions. Degrees of freedom were corrected using the G-G (Greenhouse-Geisser) ε for correlated measures. Tukey's range test was used to assess significant differences between periods of analysis (preoperative, 6 mo and 24 mo). Subjective global impression scores about health status were compared between preoperative and 24-mo postoperative periods using a Wilcoxon matched-pairs test. Analyses were performed using the Graphpad Prism 6.0d software with a two-tailed P < .05 considered as significant.
RESULTS

Patient Characteristics
The distribution of PD phenotypes, as defined by Jankovic et al, 18 is shown in Table 1 . Ten patients had severe motor fluctuations, while 7 had levodopa-induced dyskinesias.
Mean Volume and Anatomical Localization of the Campotomy
The average height (6.0 ± 2.3 mm) and diameter (3.0 ± 1.8 mm) of the lesion corresponded to a mean volume of 30 mm 3 ± 12 mm 3 after 6 mo. A typical lesion is illustrated in Figure 1A . Since the lesions were placed 1 mm above the electrophysiologically defined dorsal STN and this later varies significantly among patients, the relationship between lesions and the surrounding structures is difficult to show in the superoinferior axis by means of atlas. Given this consideration and in order to ensure a complete covering of the FF, an eventual encroaching of the extreme ventral border of overlying thalamic nuclei V.o.a and posterior (V.o.p) may have occurred, as shown in Figure 1B and 1C.
Motor Variables, Activities of Daily Living (ADL) and Drug-Induced Complications
ANOVA showed a main campotomy effect on UPDRS III scores both in off [F(11,2) = 46.70, P < .001] and on [F(11,2) = 9.53, P < .01] medication states ( Figure 2A and Table 2 ). Posthoc offstate analyses showed a 56.3% reduction at 6 mo (P < .0001) and a 43.9% reduction at 2 yr after surgery (P < .001). In onstate, a significant improvement between preoperative and 6 mo after surgery (40.7%, P < .01) was only observed (Figure 2A ). Rest tremor, rigidity and bradykinesia contralateral to campotomy had a sustained and significant improvement in offmedication condition ( Figure 2B and 2C; Table 2 ). Ipsilateral bradykinesia, tremor and rigidity were also significantly ameliorated after 6 mo, but returned close to preoperative levels after 2 yr ( Table 2 ). Motor fluctuation (items 36 to 39 of the UPDRS) also improved significantly in all 10 patients presenting this complication [Friedman statistics = 24, P < .001], showing a 71% reduction in the first 6 mo (P < .001) which remained stable until the final assessment ( Figure 2C and Table 2 ). Furthermore, a significant reduction of dyskinesia (82.5%, P = .04) was obtained at the final follow-up in the 7 patients presenting this symptom ( Figure 2D and Table 2 ).
The preoperative levodopa equivalent dosage (581.8 ± 66.76 mg/d) showed no significant reduction after surgery [F(11,2) = 3.20, P = .08]. Postoperatively, UPDRS-IV scores for drug-induced complications improved significantly [F(11,2) = 13.01, P < .01] both at 6 mo (57.9%, P < .01) and at 2 yr (60.6%, P < .01; Table 2 ). 
Axial and Gait Symptoms
As illustrated in Figure 3A , ANOVA showed a main effect of campotomy on axial symptoms in offmedication condition [F(11,2) = 11.75, P = .005], while in onmedication condition, a nonsignificant trend toward a reduction was observed [F(11,2) = 4.51, P = .06]. Post hoc analyses showed a 45.1% reduction at 6 mo (P < .01) and a 24.2% at 2 yr after surgery (P < .05) in offmedication. UPDRS item 27 (arising from chair) significantly improved by 77.3% at 6 mo (P < .001) and by 45.5% at 2 yr (P < .01 - Figure 3B ). Likewise, UPDRS item 29 (gait) improved by 72.7% at 6 mo (P < .001) and by 31.9% at 2 yr (P < .05 - Figure 3C ). Accordingly, the walking time to cover 7 m decreased by 68.6% at 6 mo (P < .001) and 43.2% at 2 yr (P < .05 - Figure 3D ). Finally, the number of steps in 7 m showed a transient decrease after 6 mo (P < .05), although this significance did not survive after 2 yr (P = .08; Table 2 ).
Nonmotor, Psychiatric and Neuropsychological Evaluation
Humor and cognition assessed by UPDRS part I improved significantly after surgery in onmedication state [F(11,2) = 6.49, P = .02]. Values decreased by 44.1% at 6 mo (P < .05) and stayed at similar levels at 2 yr (Table 2) . ADL, as indexed by UPDRS part II, also improved significantly [F(11,2) = 11.14, P < .01] both at 6 mo (53.7%, P < .01) and 2 yr (38.3%, P < .05; Table 2 ). Concerning nonmotor symptoms, pain was the only symptom that improved significantly after surgery [F(11,2) = 5.07, P < .01] ( 
QoL and Impact of PD on Global Health Status
ANOVA revealed a main campotomy effect on QoL [F(11,2) = 6.29; P = .005] ( Table 3) . Posthoc analyses showed a 52.4% improvement after 6 mo (P < .01), which was still significant after 2 yr (37.8%, P < .05). Further analyses showed significant differences after 2 yr in the following PDQ-39 domains: mobility, activity of daily living, emotional wellbeing and bodily discomfort ( Table 3 ). Concerning the subjective impact of PD on global health status, it was considered before surgery as "moderately" impaired by 3 patients, and "very" impaired by 9 patients (mean = 3.75 ± 0.45; 95% CI: 3.46-4.04). At the final followup, two patients scored their impairment as "not at all", 8 patients as "slightly" impaired and two patients as "moderately" impaired (mean = 2.0 ± 0.60; 95% CI: 1.62-2.38). A Wilcoxon test confirmed this significant effect (P < .001).
Adverse Events
Four patients presented transient somnolence, which resolved in 1 to 4 d. These patients were sleepy and sometimes confused, though able to obey simple commands (score 12 to 14 in the Glasgow Coma Scale). Lesion volume was larger than average in 2 patients (mean volume = 62 mm 3 ), while a transitory larger edema was observed in 2 other patients immediately after surgery. There was a unique case disclosing contralateral foot dystonia that gradually faded over 30 d. In this case, the lesion was more lateral and inferior (X = 8.5 mm; Z = 3 mm) than average, suggesting an encroachment on the STN. Two men presented with impulsive control disorders (hypersexuality) that completely and spontaneously resolved in the 3 following months. Short-lasting apathy, characterized by poor emotional reaction and reduced engagement in activities considered pleasant prior to surgery was observed in 2 different patients and resolved 2 wk NEUROSURGERY VOLUME 0 | NUMBER 0 | 2019 | 5 
DISCUSSION
After unilateral campotomy, we demonstrated a pronounced improvement in the contralateral motor features of PD together with an impressive reduction of both dyskinesias and motor fluctuation. Similar results are seldom described and parallel those reported by Jeanmonod's team. 14 A benefit in gait performance also occurred, suggesting the FF as a potential target to treat axial motor symptoms. Despite PD progression, severities of ipsilateral rigidity, tremor and bradykinesia at the final follow-up were similar to those observed before surgery. No difference of motor symptoms in onmedication condition was observed between preoperative and 2-yr periods, but the QoL improvement attests a global benefit mainly due to marked reduction on both medication-induced dyskinesias and motor fluctuation. Campotomy also reduced pain and facilitated ADL without persistent neuropsychological or neuropsychiatric effects. Finally, a noticeable reduction of the subjective burden of PD on global health was observed.
The rationale of this surgery is based on the interruption of pallidothalamic, nigrothalamic and pallidomesencephalic fibers involved in dysfunctional processes underlying PD. 2, 7, 11, 13 In addition, our campotomies extended towards the ventral-most portion of the V.o.a and V.o.p thalamic nuclei projecting to supplementary motor area. Although limited in volume, this thalamic involvement may have contributed to motor benefits. Rigidity was the most improved symptom in accordance with other campotomy series. 2, 13, 14 Interruption of cerebellothalamic fibers running in the medial and posterior aspect of FF may have taken part on this beneficial effect. 7, 19 Results on motor symptoms reported herein appear to be superior to those obtained after unilateral pallidotomy 20, 21 and are similar to those after Subthalamotomy. 5, 22 Additionally, campotomy allows to spare the STN as much as possible, avoiding permanent postoperative motor adverse effects as observed in a recent study. 22 Only one patient exhibited a transient right-foot dystonia which may be due to an encroachment on the dorsomedial STN. Of notice, an improvement on motor symptoms in onmedication state observed at 6 mo was lost at 2 yr. A similar trend was also observed in offmedication condition, likely reflecting PD progression. The following domains significantly improved after 6 mo and 2 yr: mobility, ADL, emotional wellbeing and bodily discomfort. Each dimension score ranges from 0 to 100 in a linear scale, in which zero is the best and 100 the worst. Values = means ± SEM; ADL = activities of daily living.
Improvements in axial symptoms support the FF as a potential target to treat these symptoms. Anatomical studies have shown that pallidotegmental fibers course through the FF 12, 23, 24 and may drive the pedunculopontine tegmental nucleus (PPN) to a dysfunctional state, participating to axial symptoms in PD. 25 Attempts to treat them by electric stimulation of PPN neurons led to discrepant results, 26 probably due to differential influences on highly heterogeneous PPN neurons. 27, 28 In this respect, modulation of PPN inputs by campotomy may provide a more specific control of axial motor symptoms than stimulation of PPN neurons. Furthermore, effects on cerebellar fibers coursing through the medial aspect of the FF may account for balance NEUROSURGERY VOLUME 0 | NUMBER 0 | 2019 | 7 improvement, leading to a faster walk despite no change in the number of steps.
As to nonmotor symptoms, it is acknowledged that they are underlined by dysfunctional sensory, associative and limbic corticobasal gangliathalamic loops. 29 Among them, pain was the only one that improved after campotomy. Several studies using different surgical approaches have already reported such an effect, 30 the origin of which remains to be clarified. The harmless nature of campotomy on neuropsychological and neuropsychiatric functions suggests that campotomy features a predominant influence on sensory-motor loops, in contrast to some deleterious effects reported after subthalamotomies 31 or pallidotomies. 21, 32 A nonsignificant trend to reduce Neuropsychiatric Inventory scores (see Table, Supplemental Digital Content) was probably due to anxiety improvement. This effect also occurred after pallidotomy and may be indirectly ascribed to motor improvement. 33 Although transient, 2 patients presented hypersexuality and 2 others apathy. We did not find a clear anatomical explanation for these effects, and suggest that transient edema over limbic parallel circuits could be at their origins. Transient somnolence occurred in 4 patients and was associated with larger lesions in 2 patients and postoperative edema in 2 others. Transient dysfunction of the pallidomesencephalic fibers modulating the reticular activating system could explain this adverse effect, which also occurred in other series. 13, 14 The large motor improvement led to a significant amelioration of the following QoL domains: mobility, ADL, emotional wellbeing and physical discomfort. No change on the subitems cognition and communication, associated with no complain about cognitive or speech decline after surgery, support the hypothesis that eventual deficits in these domains did not have clinical impact. This benefit on QoL was paralleled by a significant reduction of the subjective appraisal about PD burden on global health. This patient's assessment is noteworthy since several studies reported that, in some cases, patients are unsatisfied after surgery for movement disorders, despite a marked motor improvement. 34 The impact of surgical ablative interventions on QoL is very seldom evaluated in PD [35] [36] [37] and, in the case of campotomy, never assessed through structured and validated scales. Thus, benefits of campotomy on QoL are difficult to compare to other surgical approaches although they seem to be superior to those reported after pallidotomy. For thalamotomy or subthalamotomy studies, short follow-up limited to 12 mo impedes definitive conclusions. Finally, better scores might have been obtained after staged bilateral surgery. Although Jeanmonod's team has shown that bilateral campotomy is feasible, the specific effect of this procedure on QoL deserves future investigation.
Limitations
This study has some limitations. Only 12 out of the 19 patients could be followed during 2 yr, representing only 63% of the operated patients. Indeed, many patients in our country live far from movement disorders center and are followed-up by local Neurologists who are not acquainted with deep brain stimulation (DBS) programming. This is one of the several reasons sustaining the use of ablative therapy in movement disorders. 38 Furthermore, our results about axial effects need to be refined using more specific scales and gait laboratory methods, especially in patients with dopa-resistant symptoms. It is also important to consider that all patients underwent unilateral campotomy, which preclude us to discuss about possible benefits and safety issues of bilateral campotomy. Finally, the lack of tractography techniques in our methods is another limitation, since these techniques can improve both stereotactic targeting and lesion localization.
CONCLUSION
Our results show that unilateral campotomy improves QoL of PD patients through its remarkable ability to control most of motor symptoms, including gait performance. Its impact on nonmotor symptoms were limited to a significant reduction in pain. The reduction of PD burden on general health, associated with its innocuousness on neuropsychological and neuropsychiatric functions additionally show that campotomy may be worth considering in some patients requiring ablative surgery 38 as well as in candidates for a rescue procedure when DBS fails. 39 Finally, recent developments of less invasive therapies, such as MRI-focused ultrasound 15 and Gamma Knife (Elekta AB, Stockholm, Sweden) 40 let hope in further refinements of this ablative technique.
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